Position in ANNX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$989,423
-$136,687 QoQ
Shares Held
173,279
-14.8% QoQ
Ownership
0.085%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#80
of 216 holders
Holding Since
Mar 2021
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANNX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Rafferty Asset Management, LLC holds $331,711,589 across 163 Biotechnology names. ANNX ranks #88 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
65,798 | $32,683,840 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
38,534 | $24,027,490 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
55,332 | $16,656,591 | |
| 4 | MRNA |
Moderna, Inc.
|
111,906 | $7,836,777 | |
| 5 | INCY |
Incyte Corp
|
44,663 | $5,062,997 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
33,369 | $4,429,067 | |
| 7 | ORKA |
Oruka Therapeutics, Inc.
|
43,110 | $4,102,778 | |
| 8 | KYMR |
Kymera Therapeutics, Inc.
|
35,287 | $4,046,360 |
All Filings in ANNX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $989,423 | 173,279 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,126,110 | 203,269 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $711,052 | 141,644 | Shares | Sole | 2026-02-13 | |
| 2024-12-31 | $1,120,232 | 218,369 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $1,046,804 | 176,825 | Shares | Sole | 2024-11-13 | |
| 2021-12-31 | $823,614 | 71,681 | Shares | Sole | 2022-02-10 | |
| 2021-06-30 | $623,842 | 27,714 | Shares | Sole | 2021-08-10 | |
| 2021-03-31 | $662,647 | 23,802 | Shares | Sole | 2021-05-10 | |
| No filing history on record for this holder in this stock. | ||||||